The leaders of more than 550 healthcare organizations and 24 leading healthcare associations on May 29 wrote a letter to the top leaders of the two political parties in Congress, urging them to preserve incentive payments in Advanced Alternative Payment Models (APMs) under Medicare, in whatever final bill emerges out of Congress in the 2026 federal budget legislation, in order to avert their sunsetting. The signatories are calling on Congress to extend incentive payments and halt impending policy changes that threaten to derail progress.

HHS has proposed oversight of the 340B drug pricing program to the Centers for Medicare & Medicaid Services as part of a broader reorganization. The move, initially referenced in a preliminary memo from White House officials in April, would place the 340B program under CMS’s Program Management authority, allowing the agency to use its in-house drug pricing expertise and streamline oversight, according to HHS’s Budget in Brief.